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Introduction {#sec005}
============

Hemolysis is in most areas of medical science unwanted and it can be divided into hemolysis *in vivo* or *in vitro*.

Hemolysis *in vivo* occurs in a variety of diseases and can have both intrinsic and extrinsic causes. Intrinsic causes are either structural or functional defects in the red blood cells (RBCs) which explains diseases such as thalassemia, sickle-cell disease or enzyme deficiencies. Extrinsic causes occur in the external RBC environment, e.g. autoimmune hemolytic anemia, where antibodies directed towards RBCs are formed or infections causing hemolytic uremic syndrome where toxins lyse RBCs \[[@pone.0225777.ref001]\]. The treatment of these diseases would be to limit the hemolysis in patients, combined with blood transfusions. However, antihemolytic agents are not available on the market \[[@pone.0225777.ref002]\].

In vitro, up to 8% of all blood samples taken at an emergency department are affected by hemolysis. Hemolysis is the main (60%) cause of failed laboratory tests of blood samples from the clinic, which leads to the need for repeated blood samples from patients, more staff time, and increased economic costs \[[@pone.0225777.ref003],[@pone.0225777.ref004]\]. Hemolysis also interferes with test results, most commonly e.g. changes in potassium levels and immunological assays \[[@pone.0225777.ref005]\].

The storage of RBCs for use in clinical blood transfusions may be decreased by hemolysis \[[@pone.0225777.ref006],[@pone.0225777.ref007]\]. The US FDA and European guidelines for transfusion state that hemolysis should be \<1% and 0.8%, respectively, and that more than 75% of transfused RBCs remain in circulation 24 h after transfusion. Using contemporary storage solutions RBCs are usually able to meet these criteria for storage times for up to 42 days.

Protein carbonylation refers to a type of protein oxidation usually started by an increase in production of reactive oxygen species, which in turn starts an oxidation cascade counteracted by reducing systems such as glutathione \[[@pone.0225777.ref008]\]. However, if these systems are overwhelmed the reaction causes irreversible downstream modifications of proteins disrupting their function \[[@pone.0225777.ref009]\]. RBCs are highly resistant to oxidative stress but the systems are linked to metabolic status (glucose availability) of the RBC \[[@pone.0225777.ref010],[@pone.0225777.ref011]\]. Oxidative injury contributes to the aging and destruction of RBC, which is further compounded by glucose depletion \[[@pone.0225777.ref007],[@pone.0225777.ref012]\].

There is a need for novel exogenous reductive agents. Polyvinylalcohol-carbazate (PVAC), a polymeric compound that is highly soluble in aqueous solutions, has the capacity to bind endogenous aldehydes and neutralize oxidative stress. The objective of this study was to investigate PVAC's ability to inhibit hemolysis in the storage of RBCs.

Materials and methods {#sec006}
=====================

Preparation and characteristics PVAC {#sec007}
------------------------------------

PVAC was manufactured at Department of Chemistry---Ångström Laboratory, PVAC was manufactured at Department of Chemistry---Ångström Laboratory, Uppsala University, Sweden. PVAC is a 15- to 35-kDa polymer composed of a polyvinylalcohol (PVA) backbone that has been postmodified to partially include carbazate groups. The hydrazine moiety of the carbazate group is nucleophilic and reacts with electrophiles such as carbonyls (aldehydes or ketones) to form Schiff base like carbazones ([Fig 1](#pone.0225777.g001){ref-type="fig"}). PVAC has reactivity towards several electrophilic compounds such as aldehydes, carbonyls and ROS. Freeze-dried PVAC was dissolved in physiological saline (0.9% NaCl), vortexed for 30 s and used within 1 h of reconstitution.

![The chemical structure of PVAC.\
Polyvinylalcohol-carbazate (PVAC) condensation reaction with aldehyde at neutral conditions leads to the formation of a stable carbazone adduct and a water molecule. Unmodified repeat units of PVA are denoted with n and carbazate groups conjugated to repeat units are denoted by m. The level of substitution of PVA with carbazate groups is about 10% (n = 0.9; m = 0.1).](pone.0225777.g001){#pone.0225777.g001}

Preparation of RBC {#sec008}
------------------

For experiments investigating RBC fresh erythrocyte concentrates in Sagman solution were used. PVAC was dissolved in 0.9% NaCl and added to the erythrocyte concentrates. Whole blood was used for experiments examining biocompatibility. Both fresh erythrocyte concentrates and whole blood were obtained from healthy blood donors at the Uppsala University Hospital Blood Bank. A healthy blood donor is a member of the public that has passed the process to become a regular blood donor at the Blood Bank. This is a rigorous process that includes medical and laboratory assessments that determine the health status of the donor and that follow internationally established standards. \[[@pone.0225777.ref013]\]

Storage of RBC in test tubes {#sec009}
----------------------------

Erythrocyte concentrates were split into 5-mL portions. PVAC was dissolved in NaCl (250 μL) and added to the erythrocytes over a broad range of concentrations. As control, NaCl alone was added at a volume equivalent to that of the PVAC solution. Erythrocyte concentrates were stored in cold (4°C) or room temperature (20°C) for 2 weeks in polypropylene test tubes. For erythrocytes stored at room temperature more PVAC was added after one week because the hemolysis was expected to be greater in warm compared to cold storage. During contemporary storage of RBC the temperature is lowered to stop the metabolism and increase pH during storage. \[[@pone.0225777.ref014]\] Experiments in cold storage were done with six donors in duplicates and experiments in warm storage were done with samples from two donors in duplicates. Supernatant samples were regularly collected from the erythrocyte concentrates after centrifugation (2000 x g for 10 m). Free Hb was measured with the plasma-low Hb method (Hemocue, Angelholm, Sweden). The percentage of hemolysis was calculated by dividing the supernatant concentration by the total hemoglobin concentration for each sample.

Storage of RBC in 96-well plates {#sec010}
--------------------------------

Erythrocyte concentrates were diluted in of NaCl (v/v 100/100 μL) with or without additional PVAC, PVA (Sigma) and ethyl-carbazate (EC) (Sigma). The final volume of 200 μl was added to a round bottom 96-well cell culture plate with a lid, allowing oxygen exchange, and stored for one month at 4°C. Plates were assayed for hemolysis at day 0, 4, 7, 14, 21 and 28. At analysis the plate was spun down (2000 g x 10 min) and supernatant (100 μL) was analyzed for absorbance (540 nm) using a Synergy HTX plate reader (BioTek). The 540-nm wavelength was used because it represents the absorbance peak for the oxygenated state of hemoglobin, the most common state during storage.

Assessment of hemoglobin levels {#sec011}
-------------------------------

To exclude any direct interference of PVAC with the detection of hemolysis, whole blood was centrifuged (2000 x g for 10 min) and the erythrocyte portion was lysed using ethanol and recentrifuged. Free Hb was obtained and dissolved in PBS to a concentration of 10 g/L. PVAC was added to the free Hb and incubated for 2 h before centrifugation (2000 x g for 10 min). Free Hb was measured with the plasma-low Hb method (Hemocue). The spectrum was also analyzed using a Synergy HTX reader (BioTek) measuring absorbance between 300 and 700 nm at 10-nm increments.

Red blood cell fragility testing {#sec012}
--------------------------------

RBC from two donors in duplicates were spun down and resuspended in NaCl solution. PVAC was dissolved in NaCl and then added to the red blood cells at different concentrations. The same volume of NaCl was added to the control. The mixture was left to incubate for 1 h. Deionized water (DI water) was then mixed with 0.9% NaCl (v/v 1:1) to create a hypotonic solution. Red blood cells were incubated in the hypotonic solution for 10 min. Erythrocytes were finally spun down and the supernatant sampled and analyzed for absorbance at 540 nm using a TECAN sunrise plate reader (Tecan Trading AG, Switzerland).

Aldehyde resistance in test tubes {#sec013}
---------------------------------

After cold storage, erythrocyte concentrates from four donors in duplicates were tested for aldehyde resistance. Erythrocytes (0.9 mL) were exposed to acetaldehyde (0.1 mL, 100 μg/mL, solved in 0.9% NaCl), at a final concentration of 10 μg/mL acetaldehyde in the erythrocyte suspension. After 60 min of incubation under stirring, the erythrocyte concentrate was centrifuged (2000 x g for 10 min). Supernatants were removed and used to determine aldehyde scavenging potential, i.e. resistance to the addition of acetaldehyde. Free aldehydes were measured using the Megazyme Acetaldehyde Assay Kit (Bray, Ireland), according to manufacturer's instructions for microplate technique using 100 μL as sample volume. The plates were read at 340 nm using Synergy HTX plate reader (BioTek, Winooski, VT, USA) before and 10 min after adding aldehyde dehydrogenase. Results are reported as the change in absorbance at 340 nm.

Whole blood chamber model {#sec014}
-------------------------

Chambers, composed of a polymethylmethacrylate (PMMA) microscope slide with two PMMA rings affixed acting as wells, were filled with whole blood from three donors and hermetically covered. Chambers, pipettes, and test tubes were heparinized prior to use in the experiments according to manufacturer's protocol (Corline Biomedical, Uppsala, Sweden). Whole blood (1.5 mL) was pipetted into the heparinized chambers and PVAC dissolved in PBS (50 mg/mL, 75 μL) was added to bring the final concentration to 2.5 mg/mL within the chamber. In control chambers, PBS (75 μL) was added. A potently thrombogenic metal (titanium disc) was used as a positive control; the disc was placed as a lid to the chamber in lieu of heparinized plastic normally used, leading to an activation of both complement and coagulation. The chambers were placed on a mechanized wheel spinning at 20 rpm for 2 h, as previously described \[[@pone.0225777.ref015]\]. Blood was sampled for total platelet count (TPC) using a Sysmex XP-300 hematology analyzer (Kobe, Japan) directly after the experiment and centrifuged at 400g for 10 min. The plasma was frozen and stored at -70°C. Complement and coagulation markers were assessed with ELISA.

To detect thrombin-antithrombin (**TAT**) complexes, an antihuman thrombin antibody (Enzyme Research Labs Inc., USA) was used as the capture antibody. Bound TAT was detected with horseradish peroxidase (HRP)-conjugated antihuman antithrombin antibody (Enzyme Research Labs Inc., USA). Pooled human serum diluted in EDTA plasma was used as reference standard.

C3a is a soluble protein formed via protein cleavage during complement activation and it acts as a proinflammatory signaling molecule. To detect **C3a**, an anti-C3a monoclonal antibody 4SD17.3 (produced in house) was used as capture antibody. Bound C3a was detected with biotinylated anti-C3a antibody followed by HRP-conjugated streptavidin (GE Healthcare, Sweden). Zymosan-activated serum (ZAS), calibrated against a solution of purified C3a, was used as reference standard.

To detect sC5b-9, also known as terminal complement complex (**TCC**), the anti-neoC9 monoclonal antibody aE11 (Diatec Monoclonals AS, Oslo, Norway) was used as capture antibody. Bound sC5b-9 was detected by biotinylated polyclonal anti-C5 antibody (Biosite), followed by HRP-conjugated streptavidin (GE Healthcare). ZAS was used as reference standard. Absorbance was measured at 450 nm using a TECAN Sunrise microplate reader (Tecan Trading AG).

In the model, platelet consumption and increased levels of circulating TAT are interpreted as an increased activity of the coagulation system while increasing levels of C3a and TCC are interpreted as increased activity in the complement system.

Chemical modification of PVAC {#sec015}
-----------------------------

To visualize PVAC with flow cytometry and to perform immunoprecipitation assays a chemical modification was done with the carbazate groups and their reactivity towards electrophilic compounds. Fluorescein isothiocyanate (FITC) is a fluorochrome reactive towards most nucleophilic substances including amines and was therefore used to conjugate PVAC \[[@pone.0225777.ref016]\]. For immune precipitation, conjugation to biotin was used to create a means of extracting PVAC from a solution. Substituting carbazate groups on PVAC can theoretically affect the solubility as well as the scavenging potential of PVAC. To show the conjugation of PVAC to FITC or biotin did not have these effects, the levels of substitution were determined (supporting information, [S1 File](#pone.0225777.s007){ref-type="supplementary-material"} and [S1](#pone.0225777.s001){ref-type="supplementary-material"} and [S2](#pone.0225777.s002){ref-type="supplementary-material"} Figs). A low level of substituted carbazate groups was used (1%) which did not affect either solubility or scavenging characteristics.

In brief, PVAC was dissolved in deionized water (100 mg, 5 mL). FITC (Sigma, Upplands Vasby, Sweden) was dissolved in DMSO (WAK-Chemie, Steinbach, Germany) (1 mg, 0.1 mL). The components were mixed and allowed to react during 2 h under stirring (magnetic set at 200 rpm) in a glass beaker covered with foil. After 2 h the components were transferred to dialysis tubing, 3500 MWCO (Thermofisher), allowing unbound FITC to dissipate leaving only FITC conjugated to PVAC in the tubing. The tubing was placed in a large glass beaker filled with deionized water (DI water: reaction fluid, 1000:1). The beaker was covered with foil and set to rest overnight at room temperature under stirring (magnetic set at 200 rpm). The fluid inside the dialysis tubing was then transferred to a polystyrene tube (15 mL) and freeze dried. After freeze drying the compound was stored at -20°C until use.

To conjugate to biotin the ImmunoProbe^™^ Biotinylation Kit (Sigma) was used, according to manufacturer's instructions, with the volumes adjusted for the desired conjugation level (1%). After conjugation the Biotin-PVAC was purified with dialysis as outlined above. The product was then freeze dried and stored at -20°C until use.

Flow cytometry {#sec016}
--------------

RBCs were incubated with FITC-PVAC (100 μL, 1 mg/mL dissolved in PBS) and then washed twice in PBS before analysis. In addition, RBC were incubated in either isotonic or hypotonic NaCl (0.9--0.5%) solutions with added FITC-PVAC (1 mg/mL) for 30 min with shaking in the dark. After incubation RBCs were washed twice before analysis using an Accuri C6 flow cytometer (BD, Franklin lakes, NJ, USA). Data processing was done in FlowJo (FlowJo LCC, Ashland, OR, USA). RBCs were identified using FSC and SSC and mean fluorescent intensity (MFI) was recorded for FITC.

Immunoprecipitation (IP) and mass spectrometry (MS) {#sec017}
---------------------------------------------------

For detailed description of IP and MS please see the supporting information. ([S1 File](#pone.0225777.s007){ref-type="supplementary-material"})

Statistical analysis {#sec018}
--------------------

All data handling and statistics were done in Graphpad prism (GraphPad Software, Inc, La Jolla, CA, USA). Significant p values are defined as \<0.05 and denoted by \*. All graphs are presented with mean values and error bars as SEM. Initially Shapiro-Wilk normality test was done to determine the nature of the data. In experiments with two groups, t-tests or nonparametric counterparts were used, whereas experiments with more than two groups were analyzed by ANOVA. When experiments had two parameters, e.g. hemolysis and time, two-way ANOVA was done. In experiments with only one time point, or time-independent observations such as hemolysis after two weeks of storage, one-way ANOVA was done.

Ethical permits {#sec019}
---------------

The study was conducted within the quality system of the Uppsala University Hospital Blood Bank after a decision in the Department Board. Experiments using whole blood were approved by the local Swedish ethical committee in Uppsala, with support of the Swedish law (6§ 2003:460) regulating ethical approvals of research. The specific decision DNR 2008/264 has been appended to the supplementary information.

Results {#sec020}
=======

Storage in test tubes {#sec021}
---------------------

After storage of RBC from six donors in test tubes for two weeks at 4°C, a dose-dependent decrease in hemolysis was observed with additional PVAC. ([Fig 2A](#pone.0225777.g002){ref-type="fig"}) Hemolysis was lower with the addition of 2.5 (0.25%, 0.11--0.35, p = 0.0048) and 0.5 (0.17%, 0.01--0.33, p = 0.0478) mg/mL of PVAC compared to the control. This preventive effect on hemolysis led to further investigations using RBC duplicates from four donors, these were used an put under additional stress with an increase of temperature during storage.

![RBC stored in test tubes with PVAC added to the solution.\
**(a)** RBC stored in test tubes for two weeks at 4°C, a dose-dependent reduction of hemolysis was seen with increasing doses of PVAC. 2.5 (0.25%, 0.11--0.35, p = 0.0048) and 0.5 (0.17%, 0.01--0.33, p = 0.0478) mg/mL of PVAC compared to the control. **(b)** RBC stored in test tubes for two weeks at room temperature (20°C), where hemolysis was measured three times a week. A second dose of PVAC or NaCl was added after one week. Mean hemolysis in the control after two weeks was 3.1% and the addition of PVAC lowered hemolysis in all groups: 2.5 (1.75%, p \< 0.001), 0.5 (1.86%, p \< 0.001), 0.1 (1.87%, p \< 0.001), 0.01 mg/mL (2.15%, p = 0.001).](pone.0225777.g002){#pone.0225777.g002}

Blood storage in test tubes showed as expected an increase in hemolysis at room temperature (3.1% vs 1.08%, p = 0.0041) compared to cold storage, at 4°C. During the first week of storage, the groups did not differ significantly but as hemolysis increased during the second week there was a protective effect using PVAC. ([Fig 2B](#pone.0225777.g002){ref-type="fig"}) Hemolysis was lower in all groups with added PVAC, 2.5 (1.75%, p \< 0.001), 0.5 (1.86%, p \< 0.001), 0.1 (1.87%, p \< 0.001), 0.01 mg/mL (2.15%, p \< 0.001). The most effective prevention was seen when PVAC 2.5 mg/mL was used, with a 44% reduction in hemolysis compared to the control.

Hemoglobin was measured before and after adding the second dose of PVAC to exclude any interaction between hemoglobin and PVAC.

Levels of free hemoglobin did not differ. Moreover, the absorbance spectrum of hemoglobin was analyzed between 300 and 700 nm, with and without additional PVAC, showing no difference in the spectra. Please see supporting information for data. ([S5 Fig](#pone.0225777.s005){ref-type="supplementary-material"})

Red blood cell osmotic fragility and flow cytometry {#sec022}
---------------------------------------------------

RBCs from four blood donors exposed to a hypotonic solution were rapidly lysed. However, when red blood cells were treated with PVAC prior to exposure, a dose dependent reduction of hemolysis was seen. Incubation with PVAC at 2.5 mg/mL reduced hemolysis with a mean of 63%, 56--71, p = 0.0026, when compared to the control. ([Fig 3A](#pone.0225777.g003){ref-type="fig"}) No apparent binding was observed when RBCs from three different blood donors were mixed with FITC-PVAC in isotonic NaCl or PBS. However, in a hypotonic solution an increase in binding was observed. MFI for cells in hypotonic solution was increased, 1021 vs 335 (mean difference 686, 389--983, p = \<0.001). ([Fig 3B](#pone.0225777.g003){ref-type="fig"}) Altered concentrations of NaCl in the hypotonic solution did not differ.

![Osmotic stability of RBC stored with PVAC and association studied with flow cytometry.\
**(a)** RBC were exposed to a hypotonic solution and sampled for free hemoglobin. Hemolysis was measured as absorbance at 540 nm, with values normalized to the control. Addition of PVAC resulted in a dose-dependent reduction of hemolysis, with a mean reduction of 63% for PVAC 2.5 mg/mL compared to the control (p = 0.0026). **(b)** RBC incubated with FITC-conjugated PVAC in a hypotonic or isotonic solution. The MFI was higher when the RBC were incubated in a hypotonic solution compared to an isotonic solution, mean difference 686 (389--983, p = \<0.001).](pone.0225777.g003){#pone.0225777.g003}

Aldehyde resistance after storage {#sec023}
---------------------------------

Aldehyde levels 60 min after addition of acetaldehyde showed that RBC from four donors stored in PVAC were more efficient to neutralize acetaldehyde. The effect was dose dependent. Addition of 2.5 mg/mL PVAC reduced the amount of free aldehydes by 55% (p = \<0.001). ([Fig 4](#pone.0225777.g004){ref-type="fig"})

![Aldehyde resistance after storage with PVAC.\
RBC stored in different concentrations of PVAC were exposed to acetaldehyde. The level of free aldehydes was measured after 60 min as absorbance at 340 nm, with values normalized to the control. Addition of PVAC prior to storage resulted in a dose-dependent decrease in the level of aldehydes compared to the control.](pone.0225777.g004){#pone.0225777.g004}

Blood compatibility {#sec024}
-------------------

Blood compatibility was studied in a whole blood model where whole blood from three circulated in chambers for 2 h with adding either PVAC, a stimulating material (thrombogenic metal) or NaCl and subsequently sampled for analyses. PVAC did not activate the coagulation system as levels of TPC and TAT were comparable to the control. The complement cascade, assessed by TCC and C3a, was similarly unaffected compared to the control. ([Fig 5](#pone.0225777.g005){ref-type="fig"})

![Blood biocompatibility of PVAC in a whole blood model.\
Graphs showing the levels of coagulation markers TPC and TAT and complement activation markers TCC and C3a. No difference between PVAC and the negative control was found, supporting biocompatibility without activation of complement or coagulation.](pone.0225777.g005){#pone.0225777.g005}

Mass spectrometry {#sec025}
-----------------

PVAC conjugated to biotin associated with beads showed no difference in the gel pattern or in the final MS analysis between the proteins isolated with or without additional PVAC. For detailed results please see the supporting information. ([S1 File](#pone.0225777.s007){ref-type="supplementary-material"} and [S3](#pone.0225777.s003){ref-type="supplementary-material"} and [S4](#pone.0225777.s004){ref-type="supplementary-material"} Figs)

Influence of chemical components of PVAC {#sec026}
----------------------------------------

RBC from four donors stored in the presence of a low-molecular-weight carbazate (ethyl-carbazate, EC), PVA backbone and, PVAC displayed different patterns of hemolysis over time. During the first few days of storage the groups did not differ, but after 14 days all but the lowest concentration of EC (2.5 mg/mL, 500 and, 100 μg/mL) had a higher level of hemolysis compared to the control. ([Fig 6A](#pone.0225777.g006){ref-type="fig"}) After one month storage of RBC (from eight different blood donors), all concentrations of EC (2.5 mg/mL, 500, 100 and, 20 μg/mL, 288.5, 257.8, 120.5 and, 24.9% mean increase, respectively) and the lowest concentration of PVA (20 μg/mL, 34.1% mean increase) had a higher level of hemolysis compared to the control. All concentrations but 20 μg/mL of PVAC lowered the level of hemolysis (2.5 mg/mL, 500 and, 100 μg/mL, 39.6, 22,1 and, 19.6% mean decrease, respectively). ([Fig 6B](#pone.0225777.g006){ref-type="fig"})

![Influence of chemical components of PVAC during storage of RBC.\
Comparison between PVAC, EC and PVA during storage of RBC. In **(a)** all groups are plotted with change in levels of hemolysis over time, EC starts to deviate from the control after 7 days of storage and all EC groups had higher levels of hemolysis compared to the control. In **(b)** values after 1 month (end of storage) are shown: PVA at 100 μg/mL increased hemolysis while PVAC at 2.5 mg/mL, 500 and, 100 μg/mL decreased the levels of hemolysis compared to the control.](pone.0225777.g006){#pone.0225777.g006}

Discussion {#sec027}
==========

This is a proof-of-concept study evaluating the potential of PVAC to reduce hemolysis in different settings. Storage in test tubes demonstrated a dose-dependent effect with additional PVAC, resulting in lower levels of hemolysis. When RBCs are put under additional stress with increased storage temperature, PVAC decreased the hemolysis by about one half. PVAC also conferred proportionally higher protection of hemolysis at room temperature compared to cold storage, possibly signifying that there is an increased stress to be neutralized by PVAC at room temperature and that PVAC can act as an inhibitor when additional stress is put on the cells.

One of the factors contributing to the storage lesion is oxidative injury, \[[@pone.0225777.ref017]\] with previous studies linking increasing concentrations of malondialdehyde (MDA) to the progress of the storage lesion. \[[@pone.0225777.ref012]\] RBC stored in PVAC exhibited an increased aldehyde binding capacity, which could help blood storage by preventing oxidative by-products from injuring the RBC. In addition, when red blood cells were tested for osmotic fragility after exposure to PVAC, the level of hemolysis decreased substantially. PVAC thus seems to also provide a membrane stabilizing effect, making erythrocytes more resistant to lysis with hypotonic solution. When analyzed with flow cytometry the signal for RBC increased more than threefold when the cells were in hypotonic solution. This along with the membrane stabilizing effect indicate that PVAC associates directly with RBC during stress. When separately assessing the different components of PVAC, a low-molecular-weight carbazate (ethyl-carbazate) negatively affected storage resulting in an increase of hemolysis after storage for one month. The backbone used in PVAC synthesis, PVA, also resulted in an increase in hemolysis after one month of storage at certain concentrations. Still, this effect was not as pronounced as that of ethyl-carbazate. Indeed, PVA seemed rather inert in comparison, which is not unexpected considering its widespread use in materials commonly used in medicine and elsewhere. It is therefore not the individual chemical properties of either the carbazate moiety or the PVA backbone alone that are responsible for the observed effects but rather their combination that results in properties that are able to reduce hemolysis.

Based on the present study, PVAC seems to be a promising agent worthy of further investigation for its ability to reduce hemolysis. So far, no *in vivo* toxicity has been observed with PVAC, even in very high concentrations administered intravenously in rodents (unpublished data). Future studies will be aimed at assessing the biodistribution and clearance after *in vivo* administration of PVAC to approach clinical applications. Whereas the best potential clinical use for PVAC remains to be determined, the broader concept of neutralizing aldehydes and other reactive components through activated polymers serves as a proof-of-concept for a novel group of biologically active substances.

Supporting information {#sec028}
======================
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For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>

4\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

5\. We note that you have a patent relating to material pertinent to this article. Please provide an amended statement of Competing Interests to declare this patent (with details including name and number), along with any other relevant declarations relating to employment, consultancy, patents, products in development or modified products etc. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests> by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Additional Editor Comments (if provided):

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript, "Polyvinylalcohol-carbazate (PVAC) reduces red blood cell hemolysis" assesses whether PVAC is capable of inhibiting hemolysis in stored red blood cell units. RBC units with PVAC exhibited higher aldehyde binding and osmotic stability, resulting in reduced hemolysis. The authors postulate that PVAC administration may prevent the propagation of damage by oxidative byproducts. Further, PVAC appears to have a membrane stabilizing effect per hypotonic studies in the manuscript. Given that no toxicity has been observed with PVAC, the aldehyde scavenger represents a promising additive agent for RBC storage.

While the manuscript describes the methods in detail, the background could use more insight into current understanding of hemolysis during storage and relation to contemporary storage protocols. Further, the mechanism of carbonylation and any preventative pathways should be introduced. The methods section is thoroughly outlined, though the first section should be reworked to lay the foundation for later topics so that the section is easier to follow. The discussion ties together ideas and addresses any concerns with PVAC administration by citing toxicity data, though future studies will be necessary. Content feedback and grammatical edits may be found below.

1\. Content Feedback

1.1. Page 3, Line 49: The terminology "such anti-hemolytic agents" should not be used here, unless these agents, or the notion thereof, are directly introduced in the preceding sentence.

1.2. Page 3, Line 58: It is stated that hemolysis shortens the possible length of storage. This statement may be bolstered with specification of contemporary RBC storage parameters and how these are contingent upon in-bag hemolysis.

1.3. Page 3, Line 59: How does carbonylation occur? Are there mechanisms in vivo that prevent carbonylation and/or its propagation?

1.4. Page 5, Line 86: Please expand upon "desired buffer and concentration." While covered later in the methods, expanding upon this (i.e. listing the buffer options) would make this section more understandable and enhance cohesiveness of the methods section as a whole. Components should at least be noted for frame of reference.

1.5. Page 5, Line 87: The sentence states "the whole blood chamber model," but this model has not yet been introduced. In the same vein of 1.4, adding detail here will help with understandability of the section as a whole.

1.6. Page 5, Line 88: By which metrics was donor health assessed?

1.7. Page 5, Line 95: Why was a second addition of PVAC employed for only the warm storage group, and not the cold storage group, following one week?

1.8. Page 6, Line 109: Please specify which signature corresponds to 540 nm (Q-band) and, thus, why absorbance at this wavelength was us used in analyses.

1.9. Page 8, Line 158: Please introduce what C3a is and why it is significant for assessment.

1.10. Page 11, Line 226: What is DNR 2008/264?

1.11. Page 13, Line 284: For figure four, the Y-axis reads "free aldehydes (%)," while the caption reads "free acetaldehyde." Given that other aldehydes (i.e. MDA) may be present in the sample with storage age, perhaps the Y-axis should specify "acetaldehydes."

1.12. Page 14, Line 332: What additional stresses are present at room temperature to cause additional hemolysis? Please specify. This point may further be driven by introducing contemporary storage parameters and why cold storage is instituted (i.e. how hemolysis mechanisms are altered at lower temperatures) in the background section.

2\. Grammatical Edits

2.1. Page 3, Line 44: Prior to using the acronym "RBCs" in the body text, please introduce this in parentheses following "red blood cells." In this section, "RBCs" is used, but throughout the body "RBC" is later used to refer to plural erythrocytes. These uses need be altered to "RBCs" for clarity.

2.2. Page 3, Line 46: Please change "haemolytic" to "hemolytic" for consistency with other uses of hemolysis throughout the manuscript.

2.3. Page 3, Line 47: A comma needs to be added prior to "where toxins lyse the RBC" for readability.

2.4. Page 3, Line 49: Please change "haemolytic" to "hemolytic" (see 2.2).

2.5. Page 4, Line 82: Both uses in of "is" here should be changed to "are."

2.6. Page 6, Line 108: Minor typo of "minuntes."

2.7. Page 8, Line 172: Should "immune precipitation" read "immunoprecipitation" here?

2.8. Page 12, Line 257: Please change the comma following "spectra" to a period.

2.9. Page 13, Line 280: Please change the comma following "acetaldehyde" to a period.

2.10. Page 13, Line 290: Please begin the sentence with "blood compatibility," or some other terminology to complete this sentence.

2.11. Suppl. Line 6: "a appropriate" should be changed to "an appropriate."

2.12. Suppl. Line 28: Please change "ice cold" to "ice-cold" for consistency with previous usage.

2.13. Suppl. Line 119: "none-modified" should be change to "unmodified."

2.14. Suppl. Line 149: For consistency with other uses of "hem-" in the main text, please change "haemoglobin" to "hemoglobin."

2.15. Suppl. Line 154: See 2.14.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to reviewers

1\. Content Feedback

1.1. Page 3, Line 49: The terminology "such anti-hemolytic agents" should not be used here, unless these agents, or the notion thereof, are directly introduced in the preceding sentence.

We agree with the comment and have rephrased the statement accordingly.

1.2. Page 3, Line 58: It is stated that hemolysis shortens the possible length of storage. This statement may be bolstered with specification of contemporary RBC storage parameters and how these are contingent upon in-bag hemolysis.

We agree that this would strengthen the introduction to our work. We have expanded the introduction to include more information about the storage lesion including the role of carbonylation and how it relates to contemporary RBC storage.

1.3. Page 3, Line 59: How does carbonylation occur? Are there mechanisms in vivo that prevent carbonylation and/or its propagation?

Please see answer to 1.2

1.4. Page 5, Line 86: Please expand upon "desired buffer and concentration." While covered later in the methods, expanding upon this (i.e. listing the buffer options) would make this section more understandable and enhance cohesiveness of the methods section as a whole. Components should at least be noted for frame of reference.

We appreciate the comment by the reviewer and we have revised accordingly.

1.5. Page 5, Line 87: The sentence states "the whole blood chamber model," but this model has not yet been introduced. In the same vein of 1.4, adding detail here will help with understandability of the section as a whole.

We agree that this sentence was out of context and it has been rephrased to reference biocompatibility.

1.6. Page 5, Line 88: By which metrics was donor health assessed?

"Healthy donors" are assessed using a screening process after which their blood donations can be used for clinical transfusion. This is a rigorous process that includes medical and laboratory assessments that determine the health status of the donor and that follow internationally established standards. A brief statement has been added in the section on RBC preparation.

1.7. Page 5, Line 95: Why was a second addition of PVAC employed for only the warm storage group, and not the cold storage group, following one week?

The rationale for multiple additions in the warm storage group is that we expected a greater degree of hemolysis during warm storage, which was based on knowledge from laboratory and clinical practices utilizing cold storage to limit hemolysis. The lowering of temperature leads to a slower? metabolism which lowers oxidative stress and lysis of RBC. This was further confirmed in our study where the increase in temperature increased the hemolysis. The materials and methods has been edited to explain the rationale.

1.8. Page 6, Line 109: Please specify which signature corresponds to 540 nm (Q-band) and, thus, why absorbance at this wavelength was used in analyses.

Depending on the oxidative state of hemoglobin the absorbance spectrum changes. RBC stored in the presence of oxygen are generally in the state of oxyhemoglobin which has an absorbance peak of approximately 540 nm. We confirmed this in our study by measuring the absorbance spectrum of hemoglobin between 300 and 700 nm (in sup Fig 5). We subsequently determined that 540 nm was an appropriate wavelength for detection also in our investigations. In materials and methods we have added a paragraph to clarify the wavelengths at which hemoglobin was measured.

1.9. Page 8, Line 158: Please introduce what C3a is and why it is significant for assessment.

In materials and methods we have added a description of C3a, which is a molecule formed in the complement cascade that signals inflammation. In the whole blood model, increasing levels of C3a is an appropriate marker for general complement activation.

1.10. Page 11, Line 226: What is DNR 2008/264?

This is an identification number used by the Swedish Regional Ethical Review Board. We have clarified this in our ethical statement in the materials and methods and added the statement to our supporting information.

1.11. Page 13, Line 284: For figure four, the Y-axis reads "free aldehydes (%)," while the caption reads "free acetaldehyde." Given that other aldehydes (i.e. MDA) may be present in the sample with storage age, perhaps the Y-axis should specify "acetaldehydes."

We appreciate this astute observation and have clarified that we are indeed measuring not only acetaldehyde but in fact all free aldehydes. The method used relies on the enzyme acetaldehyde dehydrogenase and measures reduction of the substrates for the enzyme; we have also tested and confirmed that the method works with for example MDA.

1.12. Page 14, Line 332: What additional stresses are present at room temperature to cause additional hemolysis? Please specify. This point may further be driven by introducing contemporary storage parameters and why cold storage is instituted (i.e. how hemolysis mechanisms are altered at lower temperatures) in the background section.

We have added additional information in the introduction/background regarding contemporary storage parameters. Please also see our response to point 1.2.

2\. Grammatical Edits

2.1. Page 3, Line 44: Prior to using the acronym "RBCs" in the body text, please introduce this in parentheses following "red blood cells." In this section, "RBCs" is used, but throughout the body "RBC" is later used to refer to plural erythrocytes. These uses need be altered to "RBCs" for clarity.

We have changed the abbreviation so that only RBCs is used throughout the manuscript, since we only refer to red blood cells in the plural form.

2.2. Page 3, Line 46: Please change "haemolytic" to "hemolytic" for consistency with other uses of hemolysis throughout the manuscript.

2.3. Page 3, Line 47: A comma needs to be added prior to "where toxins lyse the RBC" for readability.

2.4. Page 3, Line 49: Please change "haemolytic" to "hemolytic" (see 2.2).

2.5. Page 4, Line 82: Both uses in of "is" here should be changed to "are."

2.6. Page 6, Line 108: Minor typo of "minuntes."

2.7. Page 8, Line 172: Should "immune precipitation" read "immunoprecipitation" here?

2.8. Page 12, Line 257: Please change the comma following "spectra" to a period.

2.9. Page 13, Line 280: Please change the comma following "acetaldehyde" to a period.

2.10. Page 13, Line 290: Please begin the sentence with "blood compatibility," or some other terminology to complete this sentence.

2.11. Suppl. Line 6: "a appropriate" should be changed to "an appropriate."

2.12. Suppl. Line 28: Please change "ice cold" to "ice-cold" for consistency with previous usage.

2.13. Suppl. Line 119: "none-modified" should be change to "unmodified."

2.14. Suppl. Line 149: For consistency with other uses of "hem-" in the main text, please change "haemoglobin" to "hemoglobin."

2.15. Suppl. Line 154: See 2.14.

All grammatical edits (2.2 -- 2.15) suggested by the reviewer have been corrected. Furthermore, an experienced English proof reader has reviewed the manuscript and made additional edits for readability.
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Polyvinylalcohol-carbazate (PVAC) reduces red blood cell hemolysis

PONE-D-19-23341R1

Dear Dr. Sellberg,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jeffrey Chalmers, Ph.D.

Academic Editor

PLOS ONE
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PONE-D-19-23341R1

Polyvinylalcohol-carbazate (PVAC) reduces red blood cell hemolysis

Dear Dr. Sellberg:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jeffrey Chalmers

Academic Editor

PLOS ONE
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